research use only
Cat.No.S5790
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Endogenous Metabolite Inhibitors | 4-HNE (4-Hydroxynonenal) Heparan Sulfate Oleic acid (cis-9-Octadecenoic acid) Ademetionine (S-Adenosylmethionine) Sodium L-lactate 3-Hydroxybutyric acid (BHB acid) |
|
In vitro |
DMSO
: 180 mg/mL
(380.19 mM)
Ultrasonicated;
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 473.44 | Formula | C20H23N7O7 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 58-05-9 | -- | Storage of Stock Solutions | Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt. | |
Read more about storage stability CAS number
| Targets/IC50/Ki |
Thymidylate Synthase
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2026-06-18)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06365008 | NOT_YET_RECRUITING | Unresectable/Metastatic Gastric Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2026-06 | PHASE2 |
| NCT06780111 | RECRUITING | Esophageal Squamous Cell Carcinoma |
Merck Sharp & Dohme LLC |
2025-07-30 | PHASE1; PHASE2 |
| NCT03801876 | ACTIVE_NOT_RECRUITING | Clinical Stage I Esophageal Adenocarcinoma AJCC v8; Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Thoracic Esophagus Squamous Cell Carcinoma |
NRG Oncology |
2019-06-26 | PHASE3 |
| NCT06988852 | RECRUITING | Colorectal Liver Metastasis (CRLM) |
Tongji Hospital |
2023-05-01 | PHASE2 |
| NCT00004317 | RECRUITING | Toxoplasmosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2000-07 | PHASE4 |
| NCT06958328 | RECRUITING | Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
NRG Oncology |
2025-08-21 | PHASE3 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.